VIA
ZYME icon

Vident Investment Advisory’s Zymeworks ZYME Stock Holding History

Vident Investment Advisory’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-38,784
Closed -$1.13M – 1247
2021
Q3 		$1.13M Sell
38,784
-2,770
-7% -$92.1K 0.03% 629
2021
Q2 		$1.44M Buy
41,554
+10,386
+33% +$330K 0.04% 539
2021
Q1 		$984K Hold
31,168
– – 0.03% 613
2020
Q4 		$1.47M Sell
31,168
-5,205
-14% -$242K 0.06% 413
2020
Q3 		$1.69M Sell
36,373
-2,723
-7% -$93.5K 0.08% 290
2020
Q2 		$1.41M Buy
39,096
+5,213
+15% +$192K 0.07% 349
2020
Q1 		$1.2M Sell
33,883
-2,407
-7% -$98.5K 0.08% 331
2019
Q4 		$1.65M Sell
36,290
-32,144
-47% -$1.17M 0.1% 306
2019
Q3 		$1.7M Sell
68,434
-2,592
-4% -$64.9K 0.15% 99
2019
Q2 		$1.56M Buy
+71,026
New +$1.3M 0.13% 112
2018
Q4 		– Sell
-142,306
Closed -$2.23M – 940
2018
Q3 		$2.23M Sell
142,306
-9,485
-6% -$136K 0.09% 304
2018
Q2 		$2.24M Buy
+151,791
New +$2.35M 0.09% 309

Other funds holding ZYME

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vident Investment Advisory's ZYME Position: Q4 2021 in Review

Vident Investment Advisory sold out of Zymeworks (ZYME) in Q4 2021, closing a stake of 38,784 shares — an estimated $1.13M sold.

Vident Investment Advisory first reported a position in ZYME in Q2 2018 and held it in 12 quarters. The position peaked at $2.24M in Q2 2018. 114 funds tracked by Wall St. Rank hold ZYME as of Q4 2021.

  • Vident Investment Advisory reported no remaining Zymeworks position as of Q4 2021 after selling out during the quarter.
  • Vident Investment Advisory sold 38,784 Zymeworks shares in Q4 2021, an estimated $1.13M.
  • Vident Investment Advisory first reported a position in Zymeworks in Q2 2018 and held it in 12 quarters.
  • Vident Investment Advisory's Zymeworks position peaked at $2.24M in Q2 2018.
  • 114 funds tracked by Wall St. Rank held Zymeworks as of Q4 2021.

Based on Vident Investment Advisory's 13F filing for Q4 2021, filed 14 Feb 2022.